Plasma renin and outcome in the community: data from PREVEND.

AIMS The renin-angiotensin system plays a central role in patients with established cardiovascular (CV) disease, but the prognostic effect of plasma renin in the community is unclear. METHODS AND RESULTS The relationship between plasma renin concentration and CV events was studied in 6228 subjects who were enrolled in the Prevention of REnal and Vascular ENd-stage Disease (PREVEND) study, and who were not using antihypertensive medication. Plasma renin concentration was measured using a direct automated immunochemiluminescent assay. The mean (± SD) age was 47(± 12) years, 49% were male; the mean follow-up was 10.5 years. The median (Q1-Q3) plasma renin was 17.6 (10.9-27.2) µIU/mL, and plasma aldosterone was 119 (93-153) ng/L. The primary outcome was a composite of fatal (n = 27) and non-fatal (n = 408) CV events. Adjusted for age and sex each doubling of plasma renin was associated with a hazard ratio (HR) for the primary outcome of 1.22 (95% CI: 1.04-1.43; P= 0.015). In a multivariable model, plasma renin showed a positive correlation with heart rate and male sex and a negative correlation with blood pressure, urinary sodium, glucose, and N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) (adjusted R(2): 0.167, P< 0.001). After adjustment for covariates associated with plasma renin, the HR for reaching the primary outcome was 1.28 (95% CI: 1.09-1.49, P= 0.002). Plasma renin was associated with CV events regardless of blood pressure, but in subjects using antihypertensive medication this association was absent. CONCLUSION Plasma renin concentration is associated with an increased risk for CV events in a community-based cohort not on antihypertensive medication.

[1]  S. Yusuf,et al.  Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. , 2011, European heart journal.

[2]  H. Krum,et al.  Novel therapies blocking the renin–angiotensin–aldosterone system in the management of hypertension and related disorders , 2007, Journal of hypertension.

[3]  Pim van der Harst,et al.  Nuclear hormone receptors as regulators of the renin-angiotensin-aldosterone system. , 2008, Hypertension.

[4]  K. Kalantar-Zadeh,et al.  Association of plasma renin activity and aldosterone–renin ratio with prevalence of chronic kidney disease: the Kaiser Permanente Southern California cohort , 2011, Journal of hypertension.

[5]  J. Cohn Is activation of the renin-angiotensin system hazardous to your health? , 2011, European Heart Journal.

[6]  D. de Zeeuw,et al.  N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. , 2010, European heart journal.

[7]  V. Dzau The cardiovascular continuum and renin–angiotensin–aldosterone system blockade , 2005, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[8]  W. März,et al.  Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. , 2011, European heart journal.

[9]  S Capewell,et al.  More ‘malignant’ than cancer? Five‐year survival following a first admission for heart failure , 2001, European journal of heart failure.

[10]  W. Elliott Aliskiren Reduces Blood Pressure and Suppresses Plasma Renin Activity in Combination With a Thiazide Diuretic, an Angiotensin-Converting Enzyme Inhibitor, or an Angiotensin Receptor Blocker , 2008 .

[11]  M. Gheorghiade,et al.  Rationale and design of the multicentre, randomized, double‐blind, placebo‐controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) , 2011, European journal of heart failure.

[12]  D. Silversides,et al.  Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies , 2008, Hypertension.

[13]  H. Crijns,et al.  Early expression of natriuretic peptides and SERCA in mild heart failure: association with severity of the disease. , 2001, International journal of cardiology.

[14]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[15]  R. Plehm,et al.  Elevated Blood Pressure and Heart Rate in Human Renin Receptor Transgenic Rats , 2006, Hypertension.

[16]  Sex-specific threshold levels of plasma B-type natriuretic peptide for prediction of cardiovascular event risk in a Japanese population initially free of cardiovascular disease. , 2011, The American journal of cardiology.

[17]  D. de Zeeuw,et al.  Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones. , 2000, International journal of cardiology.

[18]  A. Morganti A comparative study on inter and intralaboratory reproducibility of renin measurement with a conventional enzymatic method and a new chemiluminescent assay of immunoreactive renin , 2010, Journal of hypertension.

[19]  N. Hollenberg,et al.  Renal and Hormonal Responses to Direct Renin Inhibition With Aliskiren in Healthy Humans , 2008, Circulation.

[20]  B. Stricker,et al.  A population-based study on the prevalence and incidence of chronic kidney disease in the Netherlands , 2013, International Urology and Nephrology.

[21]  J. Connell,et al.  A screening procedure for primary aldosteronism based on the Diasorin Liaison® automated chemiluminescent immunoassay for direct renin , 2010, Annals of clinical biochemistry.

[22]  J. McMurray,et al.  Neurohumoral pathways in heart failure with preserved systolic function. , 2005, Progress in cardiovascular diseases.

[23]  E. Persohn,et al.  Effects of Aliskiren on Blood Pressure, Albuminuria, and (Pro)Renin Receptor Expression in Diabetic TG(mRen-2)27 Rats , 2008, Hypertension.

[24]  S. Solomon,et al.  Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  David C. Lee,et al.  EGF receptor activated by HB-EGF is required to calcium influx and vasoconstriction induced by endothelin-1 , 2005 .

[26]  Nish Chaturvedi,et al.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[27]  Hironori Yamamoto,et al.  EVEN STANDARD DOSE OF FUROSEMIDE IS ASSOCIATED WITH THE PROGRESSION OF CARDIORENAL SYNDROME IN PATIENTS WITH CHRONIC HEART FAILURE VIA CARDIAC SYMPATHETIC NERVE ACTIVATION , 2014 .

[28]  R. Re Tissue renin angiotensin systems. , 2004, The Medical clinics of North America.

[29]  Morris J. Brown Renin: friend or foe? , 2007, Heart.

[30]  A. Kurtz,et al.  Physiology of kidney renin. , 2010, Physiological reviews.

[31]  B. Stricker,et al.  [Plea for the retention of the Dutch National Medical Registration (LMR) to provide reliable information regarding public health and healthcare]. , 2006, Nederlands tijdschrift voor geneeskunde.

[32]  R. D. de Boer,et al.  New roles for renin and prorenin in heart failure and cardiorenal crosstalk , 2011, Heart Failure Reviews.

[33]  W. Cupples,et al.  Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure , 2012, Heart Failure Reviews.

[34]  S. Yusuf,et al.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.

[35]  D. Ganten,et al.  Tissue renin-angiotensin systems. Their role in cardiovascular disease. , 1993, Circulation.

[36]  C. Cruciat,et al.  Requirement of Prorenin Receptor and Vacuolar H+-ATPase–Mediated Acidification for Wnt Signaling , 2010, Science.

[37]  Y. Pinto,et al.  Dual pathway for angiotensin II formation in human internal mammary arteries , 1998, British journal of pharmacology.

[38]  A. Nishiyama,et al.  Regression of nephropathy developed in diabetes by (Pro)renin receptor blockade. , 2007, Journal of the American Society of Nephrology : JASN.

[39]  N. Freemantle,et al.  Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.

[40]  D. Levy,et al.  Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. , 2007, European heart journal.

[41]  J. Walls,et al.  End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? , 2001, Kidney international.

[42]  P. Harst,et al.  The fibrosis marker galectin‐3 and outcome in the general population , 2012, Journal of internal medicine.

[43]  M. Rocco,et al.  Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the Hemodialysis (HEMO) Study. , 2005, Nephrology, Dialysis and Transplantation.

[44]  B. Boehm,et al.  Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. , 2010, Journal of the American College of Cardiology.

[45]  N. Poulter,et al.  The anglo-scandinavian cardiac outcomes trial (ASCOT) , 1998 .

[46]  J. Laragh,et al.  Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. , 1991, The New England journal of medicine.

[47]  J. Laragh,et al.  Essential hypertension: renin and aldosterone, heart attack and stroke. , 1972, The New England journal of medicine.

[48]  G. Bakris,et al.  Beta blockers in the management of chronic kidney disease. , 2006, Kidney international.

[49]  A. Slabý,et al.  [Plasma renin activity and ischemic heart disease]. , 1975, Casopis lekaru ceskych.

[50]  N K Hollenberg,et al.  Is there a future for renin inhibitors? , 2001, Expert opinion on investigational drugs.

[51]  A. Danser,et al.  The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor? , 2010, Hypertension Research.

[52]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[53]  D. Grobbee,et al.  Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity , 2001, Journal of internal medicine.

[54]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.